---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107580"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2024-09-18T23:59:59+00:00"
generated_at: "2026-05-31T03:59:53.085964+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Galecto regains Nasdaq minimum bid price compliance; matter closed

## Summary
- Received Nasdaq Staff letter confirming compliance with Rule 5550(a)(2) based on bid price >= $1.00 from Aug 30 to Sep 13, 2024.
- The deficiency notice is now closed; no further action required on this matter.
- Shares continue trading on Nasdaq Capital Market under ticker GLTO.

## SEC filing metadata
- accession: 0000950170-24-107580
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2024-09-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017024107580/0000950170-24-107580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017024107580/glto-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107580
- JSON: https://secwatch.observer/filing/0000950170-24-107580.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.